Monday 26 September 2016

Paxil


See also: Generic Paxil CR


Paxil is a brand name of paroxetine, approved by the FDA in the following formulation(s):


PAXIL (paroxetine hydrochloride - suspension; oral)



  • Manufacturer: GLAXOSMITHKLINE

    Approval date: June 25, 1997

    Strength(s): EQ 10MG BASE/5ML [RLD][AB]

PAXIL (paroxetine hydrochloride - tablet; oral)



  • Manufacturer: GLAXOSMITHKLINE

    Approval date: December 29, 1992

    Strength(s): EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 30MG BASE [AB], EQ 40MG BASE [RLD][AB]

Has a generic version of Paxil been approved?


A generic version of Paxil has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Paxil and have been approved by the FDA:


paroxetine hydrochloride suspension; oral



  • Manufacturer: APOTEX INC

    Approval date: December 5, 2006

    Strength(s): EQ 10MG BASE/5ML [AB]

paroxetine hydrochloride tablet; oral



  • Manufacturer: ALPHAPHARM

    Approval date: March 8, 2004

    Strength(s): EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 30MG BASE [AB], EQ 40MG BASE [AB]


  • Manufacturer: APOTEX

    Approval date: July 30, 2003

    Strength(s): EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 30MG BASE [AB], EQ 40MG BASE [AB]


  • Manufacturer: AUROBINDO PHARMA

    Approval date: July 25, 2007

    Strength(s): EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 30MG BASE [AB], EQ 40MG BASE [AB]


  • Manufacturer: CARACO

    Approval date: June 29, 2007

    Strength(s): EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 30MG BASE [AB], EQ 40MG BASE [AB]


  • Manufacturer: MYLAN

    Approval date: March 13, 2008

    Strength(s): EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 30MG BASE [AB], EQ 40MG BASE [AB]


  • Manufacturer: TEVA

    Approval date: August 15, 2005

    Strength(s): EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 30MG BASE [AB], EQ 40MG BASE [AB]


  • Manufacturer: ZYDUS PHARMS USA

    Approval date: March 7, 2007

    Strength(s): EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 30MG BASE [AB], EQ 40MG BASE [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Paxil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Oral liquid compositions containing paroxetine resinate
    Patent 5,811,436
    Issued: September 22, 1998
    Inventor(s): Leonard; Graham Stanley & Cooper; David
    Assignee(s): SmithKline Beecham plc
    An oral liquid pharmaceutical composition comprising a paroxetine-Amberlite IRP88 complex.
    Patent expiration dates:

    • September 22, 2015


    • March 22, 2016
      ✓ 
      Pediatric exclusivity




  • Form of paroxetine hydrochloride anhydrate
    Patent 5,872,132
    Issued: February 16, 1999
    Inventor(s): Ward; Neal & Jacewicz; Victor Witold
    Assignee(s): SmithKline Beecham Corporation
    "Paroxetine hydrochloride (I) anhydrate ##STR1## free of bound propan-2-ol, and various forms thereof, are useful in the treatment of depression and other disorders for which administration of selective serotonin reuptake inhibitors are indicated."
    Patent expiration dates:

    • May 19, 2015


    • November 19, 2015
      ✓ 
      Pediatric exclusivity




  • Form of paroxetine hydrochloride anhydrate
    Patent 5,900,423
    Issued: May 4, 1999
    Inventor(s): Ward; Neal & Jacewicz; Victor Witold
    Assignee(s): SmithKline Beecham Corporation
    "Paroxetine hydrochloride (I) anhydrate ##STR1## free of bound propan-2-ol, and various forms thereof, are useful in the treatment of depression and other disorders for which administration of selective serotonin reuptake inhibitors are indicated."
    Patent expiration dates:

    • May 19, 2015


    • November 19, 2015
      ✓ 
      Pediatric exclusivity




  • Component arrangement for outboard motor
    Patent 6,062,927
    Issued: May 16, 2000
    Inventor(s): Hiraoka; Noriyoshi & Takahashi; Masanori
    Assignee(s): Sanshin Kogyo Kabushiki Kaisha
    This invention is an outboard motor for use in propelling a watercraft. The motor has a cowling in which is positioned an internal combustion engine. The internal combustion engine comprises a V shaped cylinder block cooperating with first and second cylinder heads to define first and second cylinder banks. The cylinder banks form a valley therebetween. Each of the cylinder banks include at least one combustion chamber. A crankcase is located at an end of the block opposite the heads forming a crankcase chamber. The engine also includes an exhaust system for routing the products of combustion from at least one combustion chamber and an intake system for providing air to the at least one combustion chamber. The intake system includes a single surge tank positioned between the cowling and the crankcase of the engine. At least one first intake pipe extends from the surge tank in a first direction along the cylinder block to the first cylinder head and at least one second intake pipe extends along the cylinder block to the second cylinder head.
    Patent expiration dates:

    • April 23, 2019




  • Paroxetine derivatives
    Patent 6,063,927
    Issued: May 16, 2000
    Inventor(s): Craig; Andrew Simon & Jones; Alan David & O'Keeffe; Deirdre & Ward; Neal
    Assignee(s): SmithKline Beecham plc
    Piperidine compounds, processes for preparing them, pharmaceutical compositions comprising them and their use in therapy are disclosed.
    Patent expiration dates:

    • April 23, 2019


    • October 23, 2019
      ✓ 
      Pediatric exclusivity




  • Paroxetine hydrochloride form A
    Patent 6,080,759
    Issued: June 27, 2000
    Inventor(s): Ward; Neal & Jacewicz; Victor Witold
    Assignee(s): SmithKline Beecham Corporation
    "Paroxetine hydrochloride (I) anhydrate free of bound propan-2-ol, and various forms thereof, are useful in the treatment of depression and other disorders for which administration of selective serotonin reuptake inhibitors are indicated."
    Patent expiration dates:

    • May 19, 2015


    • November 19, 2015
      ✓ 
      Pediatric exclusivity




  • Paroxetine tablets and process to prepare them
    Patent 6,113,944
    Issued: September 5, 2000
    Inventor(s): Pathak; Ram Dutta & Doughty; David George
    Assignee(s): SmithKline Beecham p.l.c.
    Invented is a novel pharmaceutical composition containing Paroxetine.
    Patent expiration dates:

    • December 14, 2014


    • June 14, 2015
      ✓ 
      Pediatric exclusivity




  • Paroxetine in the treatment of depression associated with withdrawal from heroin abuse and post-traumatic stress disorder
    Patent 6,121,291
    Issued: September 19, 2000
    Inventor(s): Gleason; Maurice
    Assignee(s): SmithKline Beecham plc
    This invention relates to the use of paroxetine or a pharmaceutically acceptable salt thereof for the treatment of post-traumatic stress disorder and depression associated with withdrawal from heroin abuse.
    Patent expiration dates:

    • March 17, 2017
      ✓ 
      Patent use: POSTTRAUMATIC STRESS DISORDER


    • March 17, 2017
      ✓ 
      Patent use: DEPRESSION


    • September 17, 2017
      ✓ 
      Patent use: POSTTRAUMATIC STRESS DISORDER
      ✓ 
      Pediatric exclusivity


    • September 17, 2017
      ✓ 
      Patent use: DEPRESSION
      ✓ 
      Pediatric exclusivity




  • Paroxetine hydrochloride form A or C
    Patent 6,133,289
    Issued: October 17, 2000
    Inventor(s): Ward; Neal & Jacewicz; Victor Witold
    Assignee(s): SmithKline Beecham Corporation
    Invented are methods of treatment using novel forms of paroxetine hydrochloride anhydrate.
    Patent expiration dates:

    • May 19, 2015
      ✓ 
      Patent use: DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER


    • November 19, 2015
      ✓ 
      Patent use: DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER
      ✓ 
      Pediatric exclusivity




  • Process for making paroxetine
    Patent 6,172,233
    Issued: January 9, 2001
    Inventor(s): Ward; Neal
    Assignee(s): SmithKline Beecham plc
    Compounds of structure (2) are prepared by reaction of an arecoline analogue of structure(4) with an organometallic compound containing an X-substituted phenyl group, such as a compound of structure (3). ##STR1## Suitably the compound of structure (3) is a Grignard reagent, where M is magnesium and Y is a halogen atom, or M may be a Group II metal and Y is a halogen atom or a second X-substituted phenyl group. When structure (3) is a Grignard reagent, the reaction is carried out either in a suitable non-ether solvent, typically a hydrocarbon or a non-reactive chlorinated hydrocarbon, or in a mixture of such a solvent with diethyl ether. Compounds of structure (2) are important intermediates in the preparation of inter alia paroxetine.
    Patent expiration dates:

    • January 15, 2018


    • July 15, 2018
      ✓ 
      Pediatric exclusivity



See also...

  • Paxil Consumer Information (Drugs.com)
  • Paxil Consumer Information (Wolters Kluwer)
  • Paxil Suspension Consumer Information (Wolters Kluwer)
  • Paxil Consumer Information (Cerner Multum)
  • Paxil Advanced Consumer Information (Micromedex)
  • Paxil AHFS DI Monographs (ASHP)
  • Paroxetine Consumer Information (Drugs.com)
  • Paroxetine Consumer Information (Wolters Kluwer)
  • Paroxetine Controlled-Release Tablets Consumer Information (Wolters Kluwer)
  • Paroxetine Mesylate Consumer Information (Wolters Kluwer)
  • Paroxetine Suspension Consumer Information (Wolters Kluwer)
  • Paroxetine Consumer Information (Cerner Multum)
  • Paroxetine Advanced Consumer Information (Micromedex)
  • Paroxetine Hydrochloride AHFS DI Monographs (ASHP)
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)